Skip to content
News

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.